Pucca, Manuela Berto; Bertolini, Thaís Barboza; Barbosa, José Elpidio; Galina, Simone Vasconcelos Ribeiro 
; Porto, Geciane Silveira
Fonte: BJPS Brazilian Journal of Pharmaceutical Sciences. Unidades: FEARP, FMRP
Assuntos: ANTICORPOS MONOCLONAIS, BIOFARMÁCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PUCCA, Manuela Berto et al. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. BJPS Brazilian Journal of Pharmaceutical Sciences, v. 47, n. 1, p. 31-39, 2011Tradução . . Acesso em: 07 maio 2024.APA
Pucca, M. B., Bertolini, T. B., Barbosa, J. E., Galina, S. V. R., & Porto, G. S. (2011). Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. BJPS Brazilian Journal of Pharmaceutical Sciences, 47( 1), 31-39.NLM
Pucca MB, Bertolini TB, Barbosa JE, Galina SVR, Porto GS. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. BJPS Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47( 1): 31-39.[citado 2024 maio 07 ]Vancouver
Pucca MB, Bertolini TB, Barbosa JE, Galina SVR, Porto GS. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. BJPS Brazilian Journal of Pharmaceutical Sciences. 2011 ; 47( 1): 31-39.[citado 2024 maio 07 ]
